METTL14 regulates chromatin bivalent domains in mouse embryonic stem cells
- PMID: 37314930
- DOI: 10.1016/j.celrep.2023.112650
METTL14 regulates chromatin bivalent domains in mouse embryonic stem cells
Erratum in
-
METTL14 regulates chromatin bivalent domains in mouse embryonic stem cells.Cell Rep. 2023 Sep 26;42(9):113116. doi: 10.1016/j.celrep.2023.113116. Epub 2023 Sep 6. Cell Rep. 2023. PMID: 37676772 No abstract available.
Abstract
METTL14 (methyltransferase-like 14) is an RNA-binding protein that partners with METTL3 to mediate N6-methyladenosine (m6A) methylation. Recent studies identified a function for METTL3 in heterochromatin in mouse embryonic stem cells (mESCs), but the molecular function of METTL14 on chromatin in mESCs remains unclear. Here, we show that METTL14 specifically binds and regulates bivalent domains, which are marked by trimethylation of histone H3 lysine 27 (H3K27me3) and lysine 4 (H3K4me3). Knockout of Mettl14 results in decreased H3K27me3 but increased H3K4me3 levels, leading to increased transcription. We find that bivalent domain regulation by METTL14 is independent of METTL3 or m6A modification. METTL14 enhances H3K27me3 and reduces H3K4me3 by interacting with and probably recruiting the H3K27 methyltransferase polycomb repressive complex 2 (PRC2) and H3K4 demethylase KDM5B to chromatin. Our findings identify an METTL3-independent role of METTL14 in maintaining the integrity of bivalent domains in mESCs, thus indicating a mechanism of bivalent domain regulation in mammals.
Keywords: CP: Molecular biology.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Y.S. is a co-founder and member of the Scientific Advisory Broad of K36 Therapeutics and ABio, Inc. Y.S. is also a member of the scientific advisory board of Epicrispr Biotechnologies, Inc., and a member of the MD Anderson External Advisory Board. Y.S. holds equity in Active Motif, K36 Therapeutics, ABio, Inc., and Epicrispr Biotechnologies, Inc.
Similar articles
-
METTL14 is a chromatin regulator independent of its RNA N6-methyladenosine methyltransferase activity.Protein Cell. 2023 Sep 14;14(9):683-697. doi: 10.1093/procel/pwad009. Protein Cell. 2023. PMID: 37030005 Free PMC article.
-
METTL3 regulates heterochromatin in mouse embryonic stem cells.Nature. 2021 Mar;591(7849):317-321. doi: 10.1038/s41586-021-03210-1. Epub 2021 Jan 27. Nature. 2021. PMID: 33505026
-
PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation.Mol Cell. 2019 Nov 7;76(3):437-452.e6. doi: 10.1016/j.molcel.2019.08.012. Epub 2019 Sep 11. Mol Cell. 2019. PMID: 31521505
-
Chromatin remodeling and bivalent histone modifications in embryonic stem cells.EMBO Rep. 2015 Dec;16(12):1609-19. doi: 10.15252/embr.201541011. Epub 2015 Nov 9. EMBO Rep. 2015. PMID: 26553936 Free PMC article. Review.
-
Regulation, functions and transmission of bivalent chromatin during mammalian development.Nat Rev Mol Cell Biol. 2023 Jan;24(1):6-26. doi: 10.1038/s41580-022-00518-2. Epub 2022 Aug 26. Nat Rev Mol Cell Biol. 2023. PMID: 36028557 Review.
Cited by
-
METTL14-mediated m6A RNA methylation promotes the osteogenic differentiation of pPDLSCs by regulating WNT3A.Odontology. 2025 Apr 18. doi: 10.1007/s10266-025-01097-2. Online ahead of print. Odontology. 2025. PMID: 40249476
-
Exercise training decreases lactylation and prevents myocardial ischemia-reperfusion injury by inhibiting YTHDF2.Basic Res Cardiol. 2024 Aug;119(4):651-671. doi: 10.1007/s00395-024-01044-2. Epub 2024 Apr 2. Basic Res Cardiol. 2024. PMID: 38563985
-
Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation.Cell. 2025 Feb 20;188(4):998-1018.e26. doi: 10.1016/j.cell.2024.12.009. Epub 2025 Jan 17. Cell. 2025. PMID: 39826545
-
METTL14 regulates proliferation and differentiation of duck myoblasts through targeting MiR-133b.PLoS One. 2025 Mar 28;20(3):e0320659. doi: 10.1371/journal.pone.0320659. eCollection 2025. PLoS One. 2025. PMID: 40153415 Free PMC article.
-
m6A modification in R-loop homeostasis: a potential target for cancer therapeutics.NAR Cancer. 2025 Aug 11;7(3):zcaf022. doi: 10.1093/narcan/zcaf022. eCollection 2025 Sep. NAR Cancer. 2025. PMID: 40809944 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous